Better Therapeutics, Inc. Common Stock
BTTX
BTTX was delisted on the 15th of March, 2024.
20 hedge funds and large institutions have $16.4M invested in Better Therapeutics, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 21 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
26% less funds holding
Funds holding: 27 → 20 (-7)
33% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 21
50% less capital invested
Capital invested by funds: $32.9M → $16.4M (-$16.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$11.1M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.16M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.7M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
+$1.79M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.67M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MI
MMCAP International
Grand Cayman,
Cayman Islands
|
-$3.49M |
| 2 |
HSBC Holdings
London,
United Kingdom
|
-$2.99M |
| 3 |
SV
Starboard Value
New York
|
-$2.99M |
| 4 |
6CM
683 Capital Management
New York
|
-$2.58M |
| 5 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.34M |
BTTX Hedge Fund Activity: Q4 2021 in Review
20 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Better Therapeutics, Inc. Common Stock (BTTX) for Q4 2021, worth a combined $16.4M — down 50% from $32.9M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of BTTX and 14 opened new positions — a net loss of 7 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $11.1M. The largest seller was MMCAP International, exiting entirely with an estimated $3.49M sold.
- 20 institutional investors held Better Therapeutics, Inc. Common Stock (BTTX) as of Q4 2021, down from 27 in Q3 2021.
- Funds reported $16.4M of Better Therapeutics, Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
- 14 funds opened new Better Therapeutics, Inc. Common Stock positions in Q4 2021 and 21 closed out, a net change of -7 holders.
- The largest Better Therapeutics, Inc. Common Stock buyer in Q4 2021 was Farallon Capital Management, an estimated $11.1M added.
- The largest Better Therapeutics, Inc. Common Stock seller in Q4 2021 was MMCAP International, an estimated $3.49M sold.
Based on aggregated 13F filings for Q4 2021.